Immunotherapy for Hepatocellular Carcinoma

Dear Colleagues,

Immunotherapy has revolutionized cancer treatment in the last decade, primarily in the form of the immune checkpoint blockade (ICB), which has transformed the standard of care for several advanced solid malignancies. ICBs combining targeted drugs have yielded promising results in the treatment of advanced hepatocellular carcinoma. Research addressing how to improve immunotherapy and discover novel immune checkpoints in clinical, experimental, and translational oncology has attracted significant attention and will benefit a greater number of HCC patients.

Recent advances in HCC immunotherapy include the following:

1. Mechanisms of action of ICBs and other immunotherapy strategies;
2. Biomarkers and metabolic imaging that predict responses to immunotherapy;
3. Latest clinical trials of ICBs and other immunotherapy strategies in different types of liver cancer;
4. Combination therapies utilizing VEGF inhibitors;
5. Challenges and future perspectives of cancer immunotherapy.

This Special Issue will update and elucidate the state of the art with respect to immunotherapy for HCC.

Dr. Max Xinxiang Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immunotherapy
• immuno-oncology
• hepatocellular carcinoma
• immune checkpoint blockade
• tumor microenvironment
• PD-1/PD-L1 interaction